CEFADROXIL IN SKIN AND SKIN-STRUCTURE FOOT INFECTIONS - A RETROSPECTIVE REVIEW

The efficacy and safety of cefadroxil in eradicating localized skin an d skin-structure infections of the foot were investigated in a retrosp ective chart review of 222 consecutive patients from two private pract ices seen over a 10-year period. Of the 189 patients for whom follow-u p data were available, 187 (99%) received cefadroxil 500 mg twice dail y, and 2 patients (1%) received 250 mg twice daily. The duration of th erapy was 2 weeks or less in 87% of patients, with a median duration o f therapy of 11.4 days (range, 5 to 35 days). Of the 189 clinically ev aluable patients, 179 (95%) achieved a favorable clinical response to treatment; of the 57 patients with microbiologic cultures, 54 (95%) ex perienced a satisfactory bacteriologic response to therapy; no adverse events related to cefadroxil therapy were identified during the revie w. The overall results from this retrospective study suggest that cefa droxil is an effective agent with a favorable safety profile for the t reatment of skin and skin-structure infections of the foot.